OHSU

IRB #

IRB00001666

Title

A Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to allow eligible, previously-treated patients with soft tissue cancer who cannot take part in other clinical trials to have access to this experimental drug.

Medical Condition(s)

Soft Tissue

Eligibility Criteria

*Patient must be 15 years or older
*Have unresectable advanced or metastatic histologically proven soft tissue sarcoma.
*Patient must have had prior chemotherapy.
*Last treatment was 3 weeks or more ago.
*Subject's medical history will be reviewed in detail for study eligibility.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Approximately 4 months on average

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Janssen Pharmaceutical Research & Development, L.L.C.

Recruitment End

Compensation Provided

No


Go Back